Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Five Prime Therapeutics, Inc.

2014 · Co-Development · Complete

Announcement Sentiment

Neutral / mixed

BMS and Five Prime entered an exclusive Phase 1a/1b clinical-collaboration agreement to evaluate cabiralizumab (FPA008, anti-CSF-1R) combined with Opdivo across six tumor types. Strategically notable as foundation for Five Prime's eventual $1.9B 2015 expanded oncology pact and Amgen's acquisition of Five Prime in 2021.

Key facts

Announced Nov 12, 2014
Closed Nov 12, 2014
Deal type Co-Development
Therapeutic area Six advanced solid tumor types
Indications Six advanced solid tumor types
Key assets FPA008 (cabiralizumab) plus nivolumab combination
Mechanism CSF-1R monoclonal antibody combined with PD-1 inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals